about
Cancer immunotherapy: the beginning of the end of cancer?Current status of immunotherapyNew strategies in immunotherapy for non-small cell lung cancerRadio-Immunotherapy-Induced Immunogenic Cancer Cells as Basis for Induction of Systemic Anti-Tumor Immune Responses - Pre-Clinical Evidence and Ongoing Clinical ApplicationsStrategies for combining immunotherapy with radiation for anticancer therapyPerspectives in the treatment of pancreatic adenocarcinomaThe Evolving Role of Immune Checkpoint Inhibitors in Cancer TreatmentThe optimal partnership of radiation and immunotherapy: from preclinical studies to clinical translationImmunotherapy of melanoma with the immune costimulatory monoclonal antibodies targeting CD137Routes of delivery for CpG and anti-CD137 for the treatment of orthotopic kidney tumors in miceThe Impact of Chemotherapy, Radiation and Epigenetic Modifiers in Cancer Cell Expression of Immune Inhibitory and Stimulatory Molecules and Anti-Tumor EfficacyThe Roles of CD137 Signaling in AtherosclerosisGalectin-9 controls the therapeutic activity of 4-1BB-targeting antibodiesTherapeutic potential of anti-CD137 (4-1BB) monoclonal antibodies.Rational combinations of immunotherapeutics that target discrete pathways.Abnormal interactions between perifollicular mast cells and CD8+ T-cells may contribute to the pathogenesis of alopecia areata.4-1BB (CD137), an inducible costimulatory receptor, as a specific target for cancer therapyA multiepitope of XBP1, CD138 and CS1 peptides induces myeloma-specific cytotoxic T lymphocytes in T cells of smoldering myeloma patients4-1BB signaling activates the t cell factor 1 effector/β-catenin pathway with delayed kinetics via ERK signaling and delayed PI3K/AKT activation to promote the proliferation of CD8+ T CellsImmunotherapy for ovarian cancer.Targeting the tumor microenvironment to enhance antitumor immune responsesNKT cell-targeted vaccination plus anti-4-1BB antibody generates persistent CD8 T cell immunity against B cell lymphoma.CD137 enhancement of HPV positive head and neck squamous cell carcinoma tumor clearance.Selection of single chain antibody fragments binding to the extracellular domain of 4-1BB receptor by phage display technology.An Effective Immuno-PET Imaging Method to Monitor CD8-Dependent Responses to Immunotherapy.Hypoxia-induced soluble CD137 in malignant cells blocks CD137L-costimulation as an immune escape mechanism.Recombinant Salmonella-based 4-1BBL vaccine enhances T cell immunity and inhibits the development of colorectal cancer in rats: in vivo effects of vaccine containing 4-1BBL.Noncanonical roles of the immune system in eliciting oncogene addictionEmerging targets in cancer immunotherapy: beyond CTLA-4 and PD-1.Human and mouse CD137 have predominantly different binding CRDs to their respective ligandsEnhanced function of cytotoxic T lymphocytes induced by dendritic cells modified with truncated PSMA and 4-1BBL.Apoptosis-regulated low-avidity cancer-specific CD8(+) T cells can be rescued to eliminate HER2/neu-expressing tumors by costimulatory agonists in tolerized miceEomesodermin is required for antitumor immunity mediated by 4-1BB-agonist immunotherapy.The TNF receptor-ligands 4-1BB-4-1BBL and GITR-GITRL in NK cell responses.Immunotherapy for the management of advanced melanoma: the next steps.Regulation of PI-3-Kinase and Akt Signaling in T Lymphocytes and Other Cells by TNFR Family MoleculesTargeting tumor-necrosis factor receptor pathways for tumor immunotherapyMicroenvironment of tumor-draining lymph nodes: opportunities for liposome-based targeted therapy.Immunotherapeutic approaches for cancer therapy: An updated review.Boosting Cancer Immunotherapy with Anti-CD137 Antibody Therapy.
P2860
Q26752277-68F82D79-8ABC-4D42-9DE2-1DA35E54862BQ26773314-230418F5-B45C-43B0-998D-35488AF9AF14Q26775385-73CA51CE-8FD2-4BE3-9A65-76A60CE79CE5Q26779221-741B219E-E923-40CD-9327-DF787FDCBC4FQ26796675-1ED79F9C-1DB7-48B0-8C87-3939C3351CDCQ26797248-6CD5A7EF-3C25-4356-A1D6-3FF56BAAD289Q27022789-4F07933C-28DA-4E99-B0C1-26387B1C7E3EQ27024106-5F497E5E-45FB-46FE-A1DC-8DB3FA466467Q27027633-354683D4-ECAD-4052-A354-1A5C2FBBAC8AQ27335400-432A28DE-D539-4676-BBD1-6D3B657112BAQ28076473-4ED90F11-1741-4C0A-BDD3-3EEDF74BF8DCQ28076613-4C7557CF-12D0-4299-8478-826DF5B97DF8Q28656460-A570ADAA-7866-4D46-8241-D1A1A4B1A9A5Q33426409-52DADC0A-D891-4665-B192-B08A613A9F2DQ33606144-66962409-266C-4E32-927A-923889D659F6Q33617937-920C4066-08E9-4B46-935F-33691BB7F87DQ34180031-61C01177-79E8-4DD5-81D0-7376D37B16BFQ34543937-FE2FAD69-2975-4670-A453-53E67E080D4FQ34854412-F9F1C437-1830-4772-B513-BDBC5C133C1BQ35164189-797823A0-D8AB-4742-AC41-C7961EBDF3F7Q35176307-F478A87C-18BB-45BB-A011-C5B6EE0513FEQ35506745-3DA75123-646D-43F5-A5C5-0E87219292F5Q35600651-7AC58935-5D2B-40AD-8F92-52B2A565FE71Q36324254-E80A2E37-B951-4D4D-8045-4D7BCB566584Q36437102-A30EABAE-48E1-4DAB-97B8-2389CA6FE55DQ36597479-E774F3D1-D420-4726-8C68-CD4F56D57AC7Q36707828-02AF1A73-A832-4B0D-BF39-4CD24AD97AA7Q36931816-27548276-F3F0-4D68-A111-D17825E1C9C0Q37158481-015D06BF-4D44-4AF1-99C5-36A8928CE5B9Q37500368-6535106C-E1C5-4D2D-9322-8D6944919BCCQ37521861-CD081AD5-CE11-4C70-B339-D948CC09915BQ37725761-AD4A8328-462D-4068-885A-7242160DAA61Q37728543-2963F9B3-1F53-4290-86C4-E992F4C3CBA6Q38073762-811305CA-489D-474F-9125-3115FD94B0F0Q38091675-3B91D052-EF78-403D-9262-B09DB5DD8C21Q38113962-ACD41C2E-6821-4B42-8B4A-B67035E56732Q38214095-4FFCB9B7-33FA-4018-A6E3-4C81225D9D97Q38266149-D4A82963-FDCD-4455-B2FD-CB34370748F3Q38388102-00C2518C-7424-4C20-AAAE-317FD5BB3AFAQ38440279-7E29410C-3B58-46BA-A6BE-190D2601C9C0
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Immunotherapy of cancer with 4-1BB.
@en
type
label
Immunotherapy of cancer with 4-1BB.
@en
prefLabel
Immunotherapy of cancer with 4-1BB.
@en
P1476
Immunotherapy of cancer with 4-1BB.
@en
P2093
Byoung S Kwon
Dass S Vinay
P304
P356
10.1158/1535-7163.MCT-11-0677
P577
2012-04-24T00:00:00Z